Search Results for "Avi Biopharma"
Original Source: AVI BioPharma
AVI BioPharma is an emerging biopharmaceutical company and a pioneer in the development of therapeutic products based upon three platform technologies: - therapeutic cancer vaccines, - gene-targeted drugs (antisense), and, - drug delivery technologies.The Company focuses its three platform technologies on two important clinical areas, cancer and cardiovascular disease. The Company is in late-stage development with Avicine, its cancer vaccine, which the Company believes may be applicable to m...
Matching Channels
Top 50 Biopharma Products 2011
Ronald A. Rader, president of the Biotechnology Information Institute provided Contract Pharma a list of the Top 57 Biopharma Products by 2011 revenues (in millions). Mr. Rader subscribes to the sam...
CurrentPartnering was established in 2007 to offer an objective and informal business tool for business development executives, providing an opportunity for the dissemination of the latest trends in...
BioPortfolio has created a number of Twitter accounts to help you keep upto date on the latest news, research papers, reports and clinical trials on a selected range of important and popular topics....
Technical Background Tumor necrosis factor (TNF) is a substance made by your body's immune system. People with inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic a...
Matching News
Biopharma Dealmaking Quarterly Statistics, Q4 2012
At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active qu...
PDL BioPharma to Hold Annual Meeting of Stockholders on May 21, 2013
INCLINE VILLAGE, Nev., March 6, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Tuesday, May 2...
How and why navigating unstructured data in biopharma industry is gaining attention
As our R&D innovation focus month continues, Will Zerhouni discusses the whys and hows of the biopharma industry’s need to navigate data. The biopharma industry and academic research centers c...
Voluntary cash offer for all outstanding shares of NOK 12.50 per share, or NOK 3 760 million total consideration Pronova's Board of Directors has unanimously recommended that shareholders accept t...
BMS biopharma partners with Quintiles for central lab services
Bristol-Myers Squibb, a big pharma company, biopharma partners with Quintiles, selecting the CRO giant to handle global central lab services for its pipeline treatments. The 5-year partnering deal als...
BRIEF: AVI Biopharma Is Now Sarepta [the Seattle Times] From Seattle Times (WA) (July 12, 2012) July 12--AVI BioPharma of Bothell has renamed itself Sarepta Therapeutics and completed a 1-for-6 revers...
14. November 2012, Lysaker, Norway: Pronova BioPharma today announced results for the third quarter and first nine months of 2012. Third quarter 2012 revenues were NOK 427.9 million, up 9 per cent...
PDL BioPharma Announces Departure of Finance VP
INCLINE VILLAGE, Nev., Jan. 30, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Caroline Krumel resigned her position as vice president of finance and principal acco...
Matching PubMed Articles
Fostering a new dialogue to improve access to finance for European biopharma SMEs.
This article reviews the current economic crisis as it impacts upon European biopharma SMEs and their ability to secure investment and funding. In particular it presents an analysis of a broader, pre-...
A selective and convenient method for the synthesis of 2-phenylaminothiazolines.
A series of 2-phenylaminothiazolines have been prepared from the corresponding N-(2-hydroxyethyl)-N'-phenylthioureas under mild reaction conditions using either thio-CDI (1,1'-thiocarbonyldiimidazole)...
The Discovery of furo2,3-cpyridine-based indanone oximes as potent and selective B-Raf inhibitors.
Virtual and high-throughput screening identified imidazo[1,2-a]pyrazines as inhibitors of B-Raf. We describe the rationale, SAR, and evolution of the initial hits to a series of furo[2,3-c]pyridine in...
Herein we describe a novel series of ATP competitive B-Raf inhibitors based on the pyrazolo[1,5-a]pyrimidine scaffold. These inhibitors exhibit both excellent cellular potency and striking B-Raf selec...
The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-Raf(V600E) kinase.
Herein we describe the discovery of a novel series of ATP competitive B-Raf inhibitors via structure based drug design (SBDD). These pyridopyrimidin-7-one based inhibitors exhibit both excellent cellu...
